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osting by EAbstract Psoriasis is a genetically determined chronic inﬂammatory and immunologically medi-
ated disease. At an early age, the presentation of psoriasis may be atypical. Among all types of
childhood psoriasis, plaque type is the most common. In this article, we report our data analysis
on the main clinical aspects of childhood psoriasis, its onset, risk factors, demographics and ther-
apeutic options. A total of 36 patients with childhood psoriasis were evaluated at the dermatology
out-patient clinic in the college of medicine at King Saud University during the period from April
2002 to June 2007. All patients were diagnosed based on clinical ﬁndings. Of the 36 patients, 24
(66.67%) had generalized plaque type psoriasis, 8 (22.2%) had guttate psoriasis, 4 (11.1%) had
mixed plaque type and guttate psoriasis, 6 (16.67%) had localized plaque type (on elbows and
knees), 4 (11.11%) had palmoplanter psoriasis and 1 (2.77%) had scalp psoriasis. Among those,
one patient had congenital psoriasis. The age of patients ranged from 8 months to 18 years
(mean = 11.3 years). There were 15 males and 21 females. The mean duration of the disease was
3.04 years and family history was positive in 10 patients (27.78%). All patients were treated by top-
ical medications and/or narrow-band ultraviolet-B phototherapy. Apart from prolonged tanning no
signiﬁcant adverse effects were reported. Of particular interest, skin cancer was not detected in this
series of children even after repeated courses. In conclusion, childhood psoriasis is more common in
girls with plaque type psoriasis being the most common type. Topical therapy is the mainstay treat-
ment for localized disease and narrow-band ultraviolet-B phototherapy is considered safe and effec-
tive for moderately severe conditions. More studies are required to deﬁne the safety of systemic
therapy and biologic treatment in this age group of psoriasis.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.4691432.
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lsevier1. Introduction
Psoriasis is a genetically determined chronic inﬂammatory dis-
order seen in 3.5% of US population (Kurd and Gelfand,
2009). The incidence in Saudi Arabia has not been precisely de-
ﬁned. It is mainly classiﬁed into two age groups: childhood
psoriasis that develops below the age of 18 years and adult-
hood psoriasis that develops after the age of 18 years. Child-
hood psoriasis is broadly sub-classiﬁed into three age groups:
Figure 1 Child with mixed guttate and plaque type psoriasis.
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psoriasis and pediatric psoriasis with psoriatic arthritis (Silver-
berg, 2009). Moreover, Congenital psoriasis (psoriasis since
birth), a distinct entity of psoriasis associated with lower prev-
alence of family history, different pattern of anatomic involve-
ment, higher fraction of erythrodermic, pustular or linear
subtypes and poor prognosis has been described. It has been
suggested that congenital psoriasis should be considered in
the category of erythematous, scaly, or pustular eruptions in
the newborn (Lehman and Rahil, 2008). The aim of this article
is to look over the clinical aspects, risk factors and therapeutic
options of childhood psoriasis in Saudi patients.
2. Demographics and onset of the disease
In this study a total of 36 patients with childhood psoriasis
were evaluated at the dermatology out-patient clinic in the col-
lege of medicine at King Saud University during the period
from April 2002 to June 2007. The age of patients ranged from
8 months to 18 years (mean = 11.3 years). The mean duration
of disease was 3.04 years. Male patients were 15 (41.67%) and
females were 21 (51.33%) (see Table 1). The incidence of child-
hood psoriasis is unknown (Marcoux and Prost, 2002), but it
has been reported that 10% of all cases occurred before the
age of 10 years and 2% at less than 2 years of age (Burden,
1999). The differences of the onset between females and males
have varied from region to region (Morris et al., 2001). In a
study from India, the age of onset of the disease ranged from
4 days to 14 years. The mean age of onset in boys was
8.1 ± 2.1 years and in girls was 9.3 ± 2.3 years. (Kumar
et al., 2004). In another report from china, a study was carried
out in 277 childhood psoriatic patients where the mean age of
onset was found to be 11 years. The male: female ratio was
1:1.13. The median age of onset of disease was 10 years (Fan
et al., 2007). Furthermore, a population based study was per-
formed in USA to assess the incidence of childhood psoriasis
which revealed that the annual incidence was 40.8 per
100,000. Authors concluded that the incidence of pediatric
psoriasis increased with age and both males and females suffer
equally (Tollefson et al., 2010). In a retrospective analysis from
Turkey, 61 children with psoriasis under age of 18 years were
evaluated. Twenty three (37.70%) were males and 38
(62.30%) were females. The mean age of patients was
9.28 ± 4.02% for females and 11.18 ± 3.85% for males. The
mean age of onset of the disease in females was
6.81 ± 4.11 years and 7.03 ± 4.28 years in males (Seyhan
et al., 2006).
3. Risk factors
In a recent report, there was no evidence to support that get-
ting affected by psoriasis before the age of 18 years inﬂuences
disease activity in later life or type of treatments used (Jager
and Jong, 2010). The association of childhood obesity and pso-
riasis is of signiﬁcance. A study was conducted to observe the
inﬂuence of obesity on childhood psoriasis, it was concluded
that being overweight is an important risk factor for the onset
of childhood psoriasis (Boccardi and Menni, 2009). It is sug-
gested that psoriasis should be added to the adverse conse-
quences of childhood obesity (Naldi et al., 1996). Seyhan
et al, from Turkey found that in most of their 61 patientsthe triggering factors were respiratory tract infections
(14.8%) and positive throat culture for group A-beta hemo-
lytic streptococci (21.3%). Also, the frequency of emotional
stress and psychiatric morbidity was 54% and 9.8%, respec-
tively. It is suggested that stress and upper respiratory tract
infections are the most important triggering factors in child-
hood and adult psoriasis. They also reported a positive family
history in 14 cases (23%) (Seyhan et al., 2006).
Apart from positive family history in one third of our pa-
tients, we did not ﬁnd any other signiﬁcant associated factors.
This might be explained by the small number of patients in our
study.
4. Clinical patterns
In our study, all patients were diagnosed based on clinical ﬁnd-
ings. Of the 36 patients, 24 (66.67%) had generalized plaque
type psoriasis, 8 (22.2%) had guttate psoriasis, 4 (11.1%)
had mixed plaque type and guttate psoriasis (see Fig. 1), 6
(16.67%) had localized plaque type (on elbows and knees), 4
(11.11%) had palmoplanter psoriasis and 1 (2.77%) had scalp
psoriasis. Among those, one patient had congenital psoriasis
(see Table 1).
Most children with psoriasis manifest with the plaque type
disease (68.6%) in similar patterns to adult patients, with le-
sions being localized to the scalp, post auricular region, el-
bows, and knees. Guttate disease is more common in
pediatric than in adult patients. It was present in 28.9% of
277 children in a Chinese survey. Other patterns in childhood
psoriasis include erythroderma (1.4%), pustular disease
including palmoplantar pustular psoriasis (1.1%), and muco-
sal glossitis (1.1%) (Fan et al., 2007). Another study has shown
that the most frequent clinical type of childhood psoriasis is
plaque type in 1302 patients (68.1%), followed by guttate pso-
riasis in 727 patients (38.0%). Erythrodermic psoriasis and
pustular psoriasis were only seen in 7.3% and 5.0% of pa-
tients, respectively (Jager and Jong, 2010). Though generalized
pustular psoriasis in children is uncommon, it may present as a
severe and potentially life-threatening disorder. Four clinical
patterns of pustular psoriasis have been described in children:
generalized pustular psoriasis, annular pustular psoriasis,
exanthematous pustular psoriasis, and localized pustular
psoriasis. Mixed variants of these patterns are also possible.
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old infant (Chao et al., 2009). In regard to congenital psoriasis,
erythrodermic and pustular variants are common presenta-
tions (Lehners-Weber et al., 1996; Al-Fouzan et al., 1990;
Lerner and Lerner, 1972; Henriksen and Zachariae, 1972).
5. Therapy
Topical treatment is the ﬁrst line therapy in childhood psoria-
sis for a limited disease. In a more severe disease, systemic ther-
apy and phototherapy are considered to control the disease.
Well-designed studies on systemic therapeutic modalities for
psoriasis in pediatric age group are meager and children are
treated with the support of data extrapolated from those in
adults (Burden, 1999).
6. Topical treatment
There are various agents frequently used as topical therapies
for childhood psoriasis. Topical corticosteroids are usually
prescribed. Mild forms of topical corticosteroids are used for
the face, whereas, moderate to potent forms are used for the
body and scalp. More than 40% of our patients were treated
by either topical corticosteroids or calcipotriene. Topical Cal-
cipotriene was proved to be efﬁcacious in childhood psoriasis
treatment in 43 children (Oranje et al., 1997). Anthralin 1%
is rarely used in childhood psoriasis because of localized irrita-
tion (Farber and Nall, 1999). Other topical agents described in
the treatment of childhood psoriasis are topical calcineurin
inhibitors, tacrolimus 0.3% ointment, and pimecrolimus 1%
cream (Stefanakiet al., 2010).
7. Phototherapy
Phototherapy is considered a safe and effective treatment for
children. Generalized or hand-foot therapy, either narrowband
ultraviolet-B (NB-UVB), broadband UVB (BB-UVB) or psor-
alen and UVA (PUVA) can be used. More than 60% of our
patients were treated with NB-UVB and satisfactory results
were observed (see Table 1). In one report, 12 weeks treatment
with NB-UVB, PASI 90 was achieved in 60% of patients, how-
ever, 10% had less than 50% improvement (Jain et al., 2007).
A series of 113 children were treated by various phototherapy
methods. Positive response was observed in 92.9% of psoriatic
patients treated by NB-UVB, in 83.3% of those treated with
PUVA and in 93.3% of those treated with BB-UVB (Ersoy-
Evans et al., 2008). NB-UVB and PUVA therapies have shown
satisfactory results in treating childhood guttate and plaque
psoriasis as marked improvement was found in 88% of 25 pa-
tients treated with these two modalities (Al-fouzan and Nanda,
1995). In another study conducted on 35 patients of childhood
psoriasis, clearance of disease was found in 63% of cases (Jury
et al., 2006). Only few cases are reported to develop erythema
and anxiety during phototherapy, otherwise, treatment is being
well tolerated (Tay et al., 1996). From our experience, photo-
therapy is considered safe and effective treatment of childhood
psoriasis where NB-UVB is favored over PUVA due to in-
creased safety proﬁle and convenience for patients. During
Phototherapy, Our patients encountered tanning effect, pruri-
tus and dryness that might be aggravated by local climate nat-
ure. In our data no single case of skin cancer was reported over10 year experience with phototherapy. Although phototherapy
is a simple, safe and effective treatment, both children and
their parents must be educated for the possible adverse effects
and the associated hazards of overexposure.
8. Oral antibiotics
Multiple studies implicate subclinical or recurrent streptococ-
cal infection as a trigger or maintenance factor in the patho-
genesis of psoriasis in children. In one study reviewing
studies and reports examining this particular relationship con-
cluded that the percentage of psoriasis patients who experi-
enced disease clearance with antibiotic therapy ranged from
0% to 55%, with no patients experiencing disease worsening
during treatment. The available evidence does not demonstrate
the efﬁcacy of antibiotic therapy in the treatment of childhood
psoriasis. Because these treatments are relatively benign com-
pared to other treatments for severe psoriasis, the use of anti-
biotic therapy may still be worth considering, especially for
those patients with recurrent streptococcal infections that seem
to trigger or maintain their skin disease (Wilson et al., 2003). A
controlled study revealed mixed results of oral antibiotics ther-
apy in childhood psoriasis (Dogan et al., 2008). In our experi-
ence the response to oral antibiotics in children with psoriasis
was variable with majority being none responsive.
9. Systemic treatment
Systemic treatment is the ultimate option in severe and uncon-
trolled cases. Systemic therapeutic options may include cyclo-
sporine (Cordoro, 2008; Mahe et al., 2001), systemic retinoids
(Davis and Krafchik, 1993; Rosinska et al., 1988) and metho-
trexate (Collin et al., 2006; Kumar et al., 1994). Limited re-
sources and studies are available to assess appropriately the
efﬁcacy and safety of these treatments in childhood psoriasis.
We have not tried such modalities in our series and no further
comments can be made.
10. Biologics
The biologic therapy namely Tumor Necrosis Factor-alpha
(TNF-alpha) blockers like etanercept and inﬂiximab has been
used recently in pediatric auto immune diseases like rheuma-
toid arthritis, TNF-a receptor 1-associated periodic syndrome
without fever (TRAPS), juvenile idiopathic arthritis and cro-
hn’s disease. Safety and efﬁcacy of etanercept therapy have
been recognized in juvenile rheumatoid arthritis patients
(Lovell et al., 2008). In a placebo-controlled randomized dou-
ble-blind trial, 211 children with plaque psoriasis were treated
with once-weekly subcutaneous injections of etanercept
(0.8 mg/kg), with a maximum dose of 50 mg. At week 12,
27% of patients treated with etanercept reached PASI 90, in
contrast to 7% of patients treated with placebo (Paller et al.,
2008). Further reports manifest the positive response of etaner-
cept (Safa et al., 2007; Papoutsaki et al., 2006). In one case
report one child with psoriasis was successfully treated with
Inﬂiximab after failure of etanercept (Farnsworth et al.,
2005). We did not use these drugs in our patients at this stage.
But we stress that these drugs cannot be used frequently until
more data are available about the risk-beneﬁt ratio of these
treatments in childhood psoriasis. With future studies proper
Table 1 Childhood psoriasis: patients series of 36 patients.
Serial No. Age (yr) Sex Duration of disease (yr) Pattern of the disease Family history Mode of treatment
1 7 f 4 Generalized (plaque type) Negative NB-UVB
2 7 f 2 Generalized (plaque type) Positive NB-UVB
3 11 f 2 Guttate type Positive NB-UVB
4 6 m 1 Mixed guttate and plaque Negative NB-UVB
5 7 m 2 Generalized (plaque type) Negative NB-UVB/Corticosteroids
6 12 f 1 Guttate type Negative NB-UVB
7 11 f 2 Mixed guttate and plaque Negative NB-UVB
8 10 f 1.5 Localized e/k (plaque type) Positive Corticosteroids
9 9 f 4 Localized e/k (plaque type) Negative Calcipotriene
10 10 f 3 Generalized (plaque type) Positive NB-UVB
11 18 f 1 Palmoplantar Negative Corticosteroids
12 15 f 2 Localized e/k (plaque type) Negative Calcipotriene
13 4 m 1.5 Guttate type Negative NB-UVB/oral antibiotic
14 0.8 m Since birth Congenital Negative Corticosteroids
15 11 m 6 Palmoplantar Negative Calcipotriene
16 4 m 1 Guttate type Negative NB-UVB/ oral antibiotic
17 8 f 2 Guttate type Positive NB-UVB
18 18 f 6 Generalized (plaque type) Negative NB-UVB/Corticosteroids
19 17 f 6 Mixed guttate and plaque Negative NB-UVB
20 12 f 0.3 Generalized (plaque type) Negative NB-UVB
21 16 f 5 Guttate type Negative NB-UVB
22 4 f 1 Scalp psoriasis Negative Corticosteroids
23 16 m 8 Generalized (plaque type) Negative NB-UVB/Corticosteroids
24 13 m 4 Localized e/k (plaque type) Negative Calcipotriene
25 12 m 0.2 Localized e/k (plaque type) Negative Corticosteroids
26 14 f 6 Palmoplantar Positive Corticosteroids
27 8 f 4 Generalized (plaque type) Negative NB-UVB
28 15 f 2 Palmoplantar Negative Corticosteroids
29 9 m 2 Guttate type Positive NB-UVB/ oral antibiotic
30 14 m 5 Generalized (plaque type) Positive NB-UVB
31 18 m 11 Generalized (plaque type) Positive NB-UVB/Corticosteroids
32 17 f 0.3 Mixed guttate and plaque Negative NB-UVB
33 6 f 1.5 Generalized (plaque type) Negative NB-UVB
34 17 m 3 Guttate type Negative NB-UVB
35 18 m 1.3 Generalized (plaque type) Positive NB-UVB/Corticosteroids
36 11 m 1 Localized e/k (plaque type) Negative Corticosteroids
e/k: Elbows and knees.
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children might be possible.
11. Conclusion
With evaluation of our series of children with psoriasis we con-
clude that childhood psoriasis is more common in females with
plaque type psoriasis being the most common type. Topical
therapy is the mainstay treatment for localized disease. At
present, NB-UVB phototherapy is a safe and effective modal-
ity for moderately severe cases particularly in children with
poor response to topical therapeutic protocols. Systemic ther-
apy and biologics should be reserved for severe and uncon-
trolled cases. More clinical studies are required to deﬁne the
safety levels of systemic therapies and biologic treatments to
properly deﬁne their position in the therapeutic ladder of child-
hood psoriasis.
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